Skip to main content

Table 4 HPV standardized prevalence (%) stratified by vaccination status and adjusted odds ratio evaluating association between HPV prevalence and vaccination status (women 18-30 years)

From: Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy

 

HPV Prevalence % (N°)

Adjusteda OR Vaccinated vs Unvaccinated

HPV types

Unvaccinated (n = 537)

Vaccinated (n = 771)

P-value

aOR (95% CI)

P-value

All types

17.1 (n 93)

15.8 (n 124)

0.39

0.89 (0.64-1.24)

0.495

 HR types

13.9 (n 76)

12.1 (n 94)

0.21

0.79 (0.55-1.13)

0.203

 LR types

6.0 (n 33)

6.1 (n 51)

0.96

1.00 (0.61-1.63)

0.989

Vaccine types

5.5 (n 30)

0.6 (n 5)

<0.001

0.10 (0.04-0.27)

<0.001

 HR vaccine types (16,18)

5.2 (n 28)

0.6 (n 5)

<0.001

0.11 (0.04-0.30)

<0.001

 LR vaccine types (6,11)

0.7 (n 4)

0.0 (n 0)

0.02

NE

-

Non-vaccine typesb

14.3 (n 78)

15.3 (n 120)

0.88

1.08 (0.76-1.52)

0.681

 HPV 31

2.1 (n 11)

1.3 (n 11)

0.58

0.89 (0.36-2.20)

0.795

 HPV 39

0.9 (n 5)

1.8 (n 17)

0.22

2.05 (0.69-6.05)

0.196

 HPV 51

1.3 (n 7)

2.9 (n 21)

0.08

2.40 (0.94-6.13)

0.067

 HPV 52

2.2 (n 12)

2.1 (n 15)

0.60

0.75 (0.33-1.70)

0.495

 HPV 56

0.9 (n 5)

1.0 (n 9)

0.94

1.17 (0.36-3.82)

0.790

 HPV 58

0.9 (n 5)

1.3 (n 11)

0.58

1.16 (0.39-3.46)

0.791

 HPV 59

0.7 (n 4)

0.5 (n 6)

0.77

0.89 (0.23-3.48)

0.870

 HPV 31, 33, 45

2.7 (n 14)

1.5 (n 13)

0.30

0.95 (0.40-2.27)

0.908

 HR-HPV no 16, 18

8.6 (n 47)

8.8 (n 73)

0.97

1.03 (0.68-1.58)

0.879

 HR-HPV no 16, 18, 31

6.9 (n 38)

8.3 (n 68)

0.56

1.14 (0.72-1.79)

0.574

 HR-HPV no 16, 18, 31, 33, 45

6.3 (n 35)

8.2 (n 67)

0.35

1.24 (0.78-1.97)

0.356

 LR non-vaccine types

4.6 (n 25)

5.2 (n 43)

0.66

1.17 (0.68-2.02)

0.576

  1. HR high risk, LR low risk, OR odds ratio, aOR adjusted OR, CI confidence interval, NE not estimable
  2. aAssociation adjusted for the following variables: marital status, smoking status, number of sexual partners in the past 6 months, number of lifetime sexual partners, and sexually transmitted diseases
  3. bHPV 33, 35, 43, 45, and 68 were tested but as the overall number of positive sample was <10 for each of these types, HPV prevalence was not stratified by vaccination status